Champions Oncology (CSBR) Research & Development (2010 - 2026)

Champions Oncology's Research & Development history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Research & Development rose 32.11% year-over-year to $2.3 million; the TTM figure through Jan 2026 stood at $8.9 million (up 29.22% YoY), while the FY2025 annual figure was $6.8 million, down 28.49% from the prior year.
• Research & Development was $2.3 million for Q1 2026 at Champions Oncology, down from $2.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $3.2 million in Q1 2023 to a low of $1.5 million in Q3 2024.
• Historically, Research & Development has averaged $2.3 million across 5 years, with a median of $2.3 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Research & Development sank 47.94% in 2024, then soared 54.88% in 2025.
• A 5-year view of Research & Development shows it stood at $2.6 million in 2022, then fell by 3.42% to $2.5 million in 2023, then slumped by 32.84% to $1.7 million in 2024, then jumped by 54.88% to $2.6 million in 2025, then declined by 13.19% to $2.3 million in 2026.
• The last three Research & Development figures came in at $2.3 million (Q1 2026), $2.6 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.